Avid Bioservices Inc (CDMO)

[biopharm]

ITUS patent another one that may require PS Targeting rights
http://m.marketwired.com/press-release/itus-corporation-announces-issuance-of-patent-on-cancer-detection-technology-nasdaq-itus-2233995.htm

ITUS and Serametrix

ITUS Corporation Forms Alliance with Serametrix Corporation
ITUS Logo (PRNewsfoto/ITUS Corporation)
NEWS PROVIDED BY

ITUS Corporation
Mar 05, 2018, 07:00 EST

SAN JOSE, Calif., March 5, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ : ITUS ) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's substantial expertise in immune monitoring assays. Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.

Dr. Amit Kumar, ITUS's Chairman and CEO, stated, "There is potential for tremendous synergy from the complementary expertise of ITUS and Serametrix. We believe that the additional capabilities provided by the Serametrix alliance will allow ITUS Corporation to expand the commercial opportunities of Cchek™. Also, we believe that the application of our artificial intelligence expertise to Serametrix's flow cytometry immuno-profiling services will allow Serametrix to offer unique and superior capabilities unavailable to other laboratories." Dr. Kumar continued, "As we develop our early cancer detection diagnostic, we expect this collaboration will create additional exposure of our technology to potential corporate partners."

Henry Hepburne-Scott, VP of Business Development of Serametrix, said, "We are delighted to enter into this agreement with ITUS as our respective technologies and capabilities are highly complementary. In particular, we believe that the application of ITUS artificial intelligence will add value to our unique and proprietary MDSC monitoring technology and we are looking forward to exploring novel opportunities with our extensive network of academic and commercial partners."

Serametrix Corporation
Serametrix provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients. In partnership with the Ludwig Institute for Cancer Research (LICR) and other leading institutes Serametrix has developed a suite of immunoassays that monitor anti-tumor immunity in patients enrolled into clinical trials for novel cancer therapies. Serametrix is part owned by the LICR.

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™ platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.

https://www.prnewswire.com/news-releases/itus-corporation-forms-alliance-with-serametrix-corporation-300607674.html

The purpse of this post is simply to show Dr. Jedd Wolchok clearly already knows of the importance of MDSC's and how it can be used as a surrogate endpoint that links to overall survival..... just as Peregrine KOL Dmitry Gabrilovich is in the middle of clearly showing. Further... Dr Jedd Wolchok seen with his ties to "Serametrix" out of San Diego and bloodwork to check for MDSC's ....

Bloodtests for overall MDSC's or subparts..etc are coming and how long before its going to be announced is the question?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=104705739

Some interesting groups at odds here as Ludwig in middle with MANY having lots to lose once PS Targeting is proven and how far the patents go....( They even go as far as forcing some to sabotage the advancement of PS Targeting and the entire platform